scispace - formally typeset
Search or ask a question
Institution

Purdue Pharma

CompanyPickering, Ontario, Canada
About: Purdue Pharma is a company organization based out in Pickering, Ontario, Canada. It is known for research contribution in the topics: Buprenorphine & Chronic pain. The organization has 622 authors who have published 691 publications receiving 31545 citations. The organization is also known as: Purdue Pharmaceuticals L.P..


Papers
More filters
Journal ArticleDOI
TL;DR: Based on the reductions in daily frequency of incontinence and micturition following 4-weeks treatment, CR oxybutynin was at least as effective as the patients' previous dose of IR oxy butynin (mean dose: 6.7 ± 2.5 mg/day).
Abstract: SUMMARYObjective: To conduct a preliminary evaluation of a new oral formulation of controlled-release (CR) oxybutynin tablet taken once-daily in patients with urinary urge incontinence.Research design and methods: A single-centre, open-label, 8-week study was conducted. Patients with urodynamically-confirmed detrusor instability, micturition frequency (> 8 voids/day) and/or urinary incontinence (> 2 incontinence periods/day) were enrolled. The study duration was 8 weeks: patients received IR oxybutynin (2.5-5 mg bid) for 2 weeks, followed by a 2-week washout/baseline period to avoid carryover effects, and oral CR oxybutynin (15 mg OD) for 4 weeks. Daily void frequency, fluid intake, urinary incontinence episodes, and spontaneously reported adverse events were recorded in a daily diary for five consecutive days in each treatment period.Results: Of 12 enrolled patients, 9 patients completed the study and were evaluable for efficacy; all patients were evaluable for safety. Compared to baseline/washout, CR ox...

1 citations

Patent
Mark A. Youngman1
04 Dec 2013
TL;DR: The present invention is directed to Buprenorphine Analog compounds of the Formula 1, Formula II, Formula III, Formula IV, and Formula V, wherein R 1, R2, R3a, R 3b, R,15a,R15b, X, Q, G, and Y are as defined in this article.
Abstract: The present invention is directed to Buprenorphine Analog compounds of the Formula 1, Formula II, Formula III, Formula IV, and Formula V, wherein R1, R2, R3a, R3b, R,15a, R15b, X, Q, G, and Y are as defined herein. Compounds of the Invention are useful for treating pain and other conditions modulated by activity of opioid receptors.

1 citations

Journal ArticleDOI
TL;DR: The 2016 SPS salary survey results showcased significant diversity regarding factors that can influence salary compensation within this discipline and revealed the level of scientific specialization embedded within the organization, presently uniquely positioned to support the dynamic career paths of current and future safety pharmacologists.

1 citations


Authors

Showing all 622 results

Network Information
Related Institutions (5)
Eli Lilly and Company
22.8K papers, 946.7K citations

87% related

Pfizer
37.4K papers, 1.6M citations

86% related

AstraZeneca
23.4K papers, 938.2K citations

84% related

GlaxoSmithKline
21.1K papers, 1.1M citations

83% related

Novartis
50.5K papers, 1.9M citations

83% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20218
202013
201915
201819
201750
201640